SB-649868

DRUG5 trials

Sponsors

GlaxoSmithKline

Conditions

InsomniaSleep DisordersSleep Initiation and Maintenance Disorders

Phase 1

Disturbed Sleep Model Study.

CompletedNCT00440323

GlaxoSmithKlineSleep Initiation and Maintenance Disorders

Start: 2007-01-05End: 2007-07-03Updated: 2017-08-17

15-Day Repeated-Dose Study With SB-649868 And Its Interaction With CYP3A4 Isoenzyme In Healthy Male Subjects.

CompletedNCT00495729

GlaxoSmithKlineSleep Initiation and Maintenance Disorders

Start: 2007-04-18End: 2007-08-04Updated: 2017-08-08

A Clinical Study to Evaluate the Pharmacokinetic Profile of SB-649868 in Elderly and Female Population

WithdrawnNCT00534872

GlaxoSmithKlineInsomnia

Start: 2007-10-31End: 2007-10-31Updated: 2015-04-17

Study to Investigate Safety, Tolerability, Pharmacokinetics and Cardiac Function After Repeat Doses of SB-649868 in Healthy-volunteers

CompletedNCT01030939

GlaxoSmithKlineSleep Disorders

Start: 2009-08-27End: 2010-01-06Updated: 2017-06-20

Phase 2

To Evaluate The Effects Of SB-649868 (10, 30 Mg And 60 Mg) On Subjects With Primary Insomnia

CompletedNCT00426816

GlaxoSmithKlineSleep Initiation and Maintenance Disorders

Start: 2006-12-31End: 2007-05-31Updated: 2012-08-13